Literature DB >> 8730253

Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients.

F Parente1, G Maconi, S Bargiggia, E Colombo, G Bianchi Porro.   

Abstract

AIM: To compare the eradicating capacity of two different antibiotic-lansoprazole combinations (amoxycillin vs. standard triple therapy) with that of lansoprazole alone in Helicobacter pylori-positive duodenal ulcer patients.
METHODS: Ninety-six out-patients with H. pylori-positive duodenal ulcer were randomly assigned to receive one of the following three antiulcer regimens: (1) lansoprazole 30 mg b.d. for 4 weeks plus amoxycillin 1 g t.d.s. during the last 2 weeks; or (2) lansoprazole 30 mg once daily for 4 weeks plus classical triple therapy (tripotassium dicitratobismuthate 240 mg b.d., amoxycillin 1 g t.d.s. and tinidazole 500 mg b.d.) for the last 2 weeks; or (3) lansoprazole 30 mg once daily for 4 weeks. Endoscopy was repeated at the end of treatment and 1 month later. A rapid urease test and histology were used to determine H. pylori status.
RESULTS: Duodenal ulcer healing rates at 4 weeks were 96% after both lansoprazole with amoxycillin, and lansoprazole with triple therapy, and 97% after lansoprazole alone. Eradication of H. pylori was significantly better with lansoprazole with triple therapy than with either lansoprazole with amoxycillin or lansoprazole alone (90% vs. 55% vs. 3%, respectively).
CONCLUSION: Classical triple therapy combined with lansoprazole is significantly more effective than the lansoprazole with amoxycillin combination for the eradication of H. pylori in duodenal ulcer patients pre-treated with lansoprazole.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8730253     DOI: 10.1046/j.1365-2036.1996.729121000.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  3 in total

Review 1.  Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.

Authors:  H D Langtry; M I Wilde
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

2.  Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy.

Authors:  G Bianchi Porro; F Parente; V Imbesi; F Montrone; I Caruso
Journal:  Gut       Date:  1996-07       Impact factor: 23.059

Review 3.  Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people.

Authors:  Alexander C Ford; Kurinchi Selvan Gurusamy; Brendan Delaney; David Forman; Paul Moayyedi
Journal:  Cochrane Database Syst Rev       Date:  2016-04-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.